Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual ConferenceRead More
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEERead More
Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 SymposiumRead More
Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™Read More